FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Horizon Pharma Pays $145 Million For And Its Rare Eye Disease Drug May 7, 2017 Senti Biosciences Raises $53 Million from Amgen and Others in Series A Financing February 26, 2018 Inaugural Asia Pacific GAMP Data Integrity Conference Announced July 16, 2017
